Publication at Second Faculty of Medicine |
2009
Abstract
Sitagliptin is the player who had just entered the European scene by the pharmacological company called Januvia. Worldwide, it aimed high expectations, since it will launch a groundbreaking era in the treatment of an epidemic of this century, the second type of diabetes mellitus.